Ascletis Submits Two IND Applications to the U.S. FDA for the Treatment of Obesity: ASC36 Once-Monthly Injection, a Peptide Amylin Receptor Agonist, and ASC36_35 F…

ASC36_35 FDC, a once-monthly subcutaneous (SQ) injection co-formulation of ASC36 and ASC35, is a potentially first-in-class ...
아시아경제

"One-Minute Injection" SC Formulation Competition Heats Up... Royalty Structures Put to the Test

As the core substance patents of Halozyme Therapeutics, a leading U.S. biotechnology company specializing in subcutaneous (SC) formulation technology, are set to expire sequentially from next year ...
Pharmabiz

Ascletis submits two IND applications to the US FDA to treat obesity: ASC36 once-monthly injection & ASC36_35 FDC once-monthly injection

Ascletis submits two IND applications to the US FDA to treat obesity: ASC36 once-monthly injection & ASC36_35 FDC once-monthly injection: Hong Kong Tuesday, July 7, 2026, 12:00 Hr ...
Nasdaq

Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®

SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Eisai Co., Ltd. obtained marketing authorization approval in January 2024 from the ...
GEN

The Final Formulation: Last Step in the Drug Development Journey

To optimize the final formulation for a drug, it must meet many criteria beyond producing a safe and effective product. For example, it must be stable and amenable to various manufacturing steps, such ...

Clearmind Reports Successful Formulation Feasibility Study Supporting Potential New Additional Route of Administration Development for MEAI

Clearmind Medicine Inc. (Nasdaq: CMND), a clinical-stage a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, ...
PharmTech

How To Develop Sterile Drug Products for Subcutaneous Use for Biologics

Gain valuable insights into pharmaceutical development for sterile subcutaneous products with this exclusive webinar. Learn about critical development strategies and scenarios for initial launches and ...
FiercePharma

Sandoz launches a new, ready-to-use formulation of argatroban injection (in Sodium Chloride)

Sandoz today announced the US launch of argatroban injection (in sodium chloride), the first ready-to-use alternative to Pfizer's concentrate formulation, following the US Food and Drug Administration ...